Citations

Showing 10 of 108119 citations.

­Book‐shaped decellularized tendon matrix scaffold combined with bone marrow mesenchymal stem cells‐sheets for repair of achilles tendon defect in rabbit
Xie, Shanshan , Zhou, Yongchun , Tang, Yifu , Chen, Can , Li, Shengcan , Zhao, Chunfeng , Lü, Hongbin , Lu, Hongbin , Hu, Jianzhong

Mayo Clinic

Journal of Orthopaedic Research | February 28, 2019 | Volume: 37 | Issue: 4 | Pages: 887-897

10.1002/jor.24255 | PMID 30816590 Get It

ABSTRACTTissue‐engineering approaches have great potential to improve the treatment of tendon injuries which are major musculoskeletal disorders. The purpose of this study was to assess the tissue engineering potential of a novel multilayered decellularized tendon “book” scaffold with bone marrow mesenchymal stem cells (BMSCs) sheets for repair of an Achilles tendon defect in a rabbit model. In this study, we developed a novel book‐shaped decellularized scaffold derived from the extracellular matrix of tendon tissues from New Zealand white rabbits. Hematoxylin and eosin (H&E) staining, 4′, 6‐diamidino‐2‐phenylindole (DAPI) staining, DNA quantitation, and scanning electron microscopy (SEM) confirmed the efficiency of decellularization. After culturing BMSCs on decellularized scaffolds, 3‐(4, 5‐dimethylthiazol‐2‐yl)‐2, 5‐diphenyltetrazolium bromide (MTT) assay, SEM, quantitative real time polymerase chain reaction (qRT‐PCR), and immunofluorescence analysis demonstrated that decellularized scaffolds have the capacity to yield homogeneous distribution and alignment of BMSCs, as well as support their differentiation into tendon. Tenomodulin and Alpha‐1 collagen type I are important indicators for evaluating tenogenic differentiation of BMSCs. When decellularized “book” scaffolds with BMSCs sheets were used to repair a 1 mm Achilles tendon defect, histomorphological analysis, immunohistochemical assessment, and biomechanical testing showed that the book‐shaped decellularized tendon matrix scaffold and BMSCs sheets could promote the regeneration of type I collagen at the wound site during healing, and improve the mechanical properties of the repaired tendon. Therefore, the results of this study suggest that the novel decellularized “book” tendon scaffolds combined with BMSCs sheets have therapeutic effects on improving the healing quality of the Achilles tendon. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 9999:1–11, 2019.
Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Ellenberg, Susan S. , Krowka, Michael J. , Goldberg, David S. , Vargas, Hugo E. , Koch, David , Sharkoski, Tiffany, Al‐Naamani, Nadine , Fox, Alyson N. , Levitsky, Joshua, Oh, Jae K. , Lin, Grace , Song, Nianfu, Mottram, Carl, Doyle, Margaret F. , Gupta, Samir , Fallon, Michael B. , Vargas, Hugo, Vargas, Hugo E , Al-Naamani, Nadine , Kawut, Steven M. , Brown, Robert S. , Song, Nianfu, Kaplan, David E. , Koch, David

Mayo Clinic

Liver Transplantation | February 28, 2019 | Volume: 25 | Issue: 8 | Pages: 1155-1164

10.1002/lt.25438 | PMID 30816637 Get It

The tyrosine kinase inhibitor sorafenib improves hepatopulmonary syndrome (HPS) in an experimental model. However, the efficacy and adverse effect profile in patients with HPS are unknown. We aimed to determine the effect of sorafenib on the alveolar‐arterial oxygen gradient (AaPO2) at 3 months in patients with HPS. We performed a randomized, double‐blind, placebo‐controlled parallel trial of sorafenib in patients with HPS at 7 centers. A total of 28 patients with HPS were randomized to sorafenib 400 mg by mouth daily or a matching placebo in a 1:1 ratio. We found no statistically significant difference in the median change in AaPO2 from baseline to 12 weeks between the patients allocated to sorafenib (4.5 mm Hg; IQR, –3.8 to 7.0 mm Hg) and those allocated to placebo (–2.4 mm Hg; IQR, –4.8 to 8.2 mm Hg; P = 0.70). There was also no difference between the groups in terms of degree of intrapulmonary shunting by contrast echocardiography. Sorafenib significantly reduced circulating levels of angiogenic markers, including vascular endothelial growth factor receptors (P < 0.01) and TIE2‐expressing M2 monocytes (P = 0.03), but it reduced the mental component scores of the Short Form 36 (P = 0.04), indicating a worse quality of life. In conclusion, sorafenib did not change the AaPO2 or other disease markers at 3 months in patients with HPS. Alternative antiangiogenic therapies or treatments targeting other pathways should be investigated.
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Preadmission Corticosteroid Therapy and the Risk of Respiratory Failure in Adults Without HIV Presenting With Pneumocystis Pneumonia
Wieruszewski, Patrick M. , Frazee, Erin N. , Barreto, Jason N. , Yadav, Hemang , Tosh, Pritish K. , Mara, Kristin C. , Mara, Kristin C , Wieruszewski, Patrick M , Limper, Andrew H.

Mayo Clinic

Journal of Intensive Care Medicine | February 28, 2019 | Volume: 35 | Issue: 12 | Pages: 1465-1470

10.1177/0885066619834242 | PMID 30813829 Get It

Background: Corticosteroid therapy is a well-recognized risk factor for Pneumocystis pneumonia (PCP); however, it has also been proposed as an adjunct to decrease inflammation and respiratory failure. Objective: To determine the association between preadmission corticosteroid use and risk of moderate-to-severe respiratory failure at the time of PCP presentation. Methods: This retrospective cohort study evaluated HIV-negative immunosuppressed adults diagnosed with PCP at Mayo Clinic from 2006 to 2016. Multivariable regression models were used to evaluate the association between preadmission corticosteroid exposure and moderate-to-severe respiratory failure at presentation. Results: Of the 323 patients included, 174 (54%) used preadmission corticosteroids with a median daily dosage of 20 (interquartile range: 10-40) mg of prednisone or equivalent. After adjustment for baseline demographics, preadmission corticosteroid therapy did not decrease respiratory failure at the time of PCP presentation (odds ratio: 1.23, 95% confidence interval: 0.73-2.09, P = .38). Additionally, after adjusting for inpatient corticosteroid administration, preadmission corticosteroid use did not impact the need for intensive care unit admission ( P = .98), mechanical ventilation ( P = .92), or 30-day mortality ( P = .11). Conclusions: Corticosteroid exposure before PCP presentation in immunosuppressed HIV-negative adults was not associated with a reduced risk of moderate-to-severe respiratory failure.
Percutaneous Pedicle Screw Fixation Alone Versus Debridement and Fusion Surgery for the Treatment of Early Spinal Tuberculosis: A Retrospective Cohort Study
Guo, Song , Zhu, Kai , Zhang, Shuya , Yang, Mingjie , Yan, Meijun , Li, Xinhua , Pan, Jie , Li, Lijun , Wang, Zhigang , Tan, Jun , Ma, Bin

Mayo Clinic

Medical Science Monitor | February 27, 2019 | Volume: 25 | Issue: No issue available | Pages: 1549-1557

10.12659/msm.912538 | PMID 30811378 Get It

Patient-Experience Data and Bias — What Ratings Don’t Tell Us
Poole, Kenneth , Poole, Kenneth G

Mayo Clinic

New England Journal of Medicine | February 27, 2019 | Volume: 380 | Issue: 9 | Pages: 801-803

10.1056/nejmp1813418 | PMID 30811905 Get It

The Protective Effect of Breast Implants in Penetrating Trauma
Pannucci, Christopher J., Kurnik, Nicole M. , Brzezienski, Mark A., Rebecca, Alanna M. , Higdon, Kent

Mayo Clinic

Aesthetic Surgery Journal Open Forum | February 27, 2019 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/asjof/ojz004 Get It

Abstract Breast implants are typically placed for cosmetic or reconstructive purposes, and are recognized to have a substantial impact on aesthetics and quality of life. In addition, the presence of a breast implant on the chest wall has a potential benefit of force diffusion or force absorption in traumatic injury. This article reports a series of three patients with preexisting breast implants who suffered penetrating chest trauma. In each case, the presence of a breast implant was potentially lifesaving. We describe the cases in detail, provide a conceptual discussion, and discuss directions for future research. Level of Evidence: 5
MetaMarker: a pipeline for de novo discovery of novel metagenomic biomarkers
Tran, Nhan L. , Swanson, Kristin R. , Boardman, Lisa A, Sun, Hongzhe , Wang, Junwen , Koohi-Moghadam, Mohamad, Swanson, Kristin R , Wang, Junwen , Koohi‐Moghadam, Mohamad , Borad, Mitesh J. , Boardman, Lisa A, Tran, Nhan L

Mayo Clinic

Bioinformatics | February 27, 2019 | Volume: 35 | Issue: 19 | Pages: 3812-3814

10.1093/bioinformatics/btz123 | PMID 30825371 Get It

Abstract Summary We present MetaMarker, a pipeline for discovering metagenomic biomarkers from whole-metagenome sequencing samples. Different from existing methods, MetaMarker is based on a de novo approach that does not require mapping raw reads to a reference database. We applied MetaMarker on whole-metagenome sequencing of colorectal cancer (CRC) stool samples from France to discover CRC specific metagenomic biomarkers. We showed robustness of the discovered biomarkers by validating in independent samples from Hong Kong, Austria, Germany and Denmark. We further demonstrated these biomarkers could be used to build a machine learning classifier for CRC prediction. Availability and implementation MetaMarker is freely available at https://bitbucket.org/mkoohim/metamarker under GPLv3 license. Supplementary information Supplementary data are available at Bioinformatics online.
Survival Differences in Women and Men After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy
Meghji, Zahara, Nguyen, Anita , Fatima, Benish , Geske, Jeffrey B. , Ommen, Steve R. , Lahr, Brian D. , Geske, Jeffrey B , Nishimura, Rick A. , Dearani, Joseph A. , Schaff, Hartzell V.

Mayo Clinic

JAMA Cardiology | February 27, 2019 | Volume: 4 | Issue: 3 | Pages: 237

10.1001/jamacardio.2019.0084 | PMID 30810698 Get It